# Spironolactone After Liver Transplant

> **NCT02883400** · PHASE4 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 30 (actual)

## Conditions studied

- Transplant, Liver

## Interventions

- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT02883400
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883400, "Spironolactone After Liver Transplant". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT02883400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*